Adjuvant chemotherapy for operable breast cancer: old vs new schema

Breast Cancer Res · 2005 · PMC4231905

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Of note, the 3-year joint efficacy analysis of the National Epirubicin Adjuvant Trial (NEAT) and of the Scottish Cancer Trials Breast Group reported a highly significant benefit in favor of the sequential regimen, supporting the hypothesis that the sequential administration of single-agent anthracyclines given upfront before CMF can indeed improve treatment outcome.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.